{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T11:19:41Z","timestamp":1793272781787,"version":"4.5.0"},"reference-count":24,"publisher":"Wiley","issue":"24","license":[{"start":{"date-parts":[[2025,12,21]],"date-time":"2025-12-21T00:00:00Z","timestamp":1766275200000},"content-version":"vor","delay-in-days":20,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Prostate cancer is among the most prevalent malignancies worldwide, and cardiovascular disease (CVD) is a major non\u2010cancer cause of death in affected patients. Androgen deprivation therapy (ADT), a mainstay treatment, has raised concerns about cardiotoxicity, yet the CVD risks of individual ADT agents remain unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To assess cardiovascular adverse events (AEs) associated with specific ADT drugs using data from the U.S. FDA Adverse Event Reporting System (FAERS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>AE reports related to ADT drugs were extracted from FAERS (Q1 2004\u2013Q3 2024). Disproportionality analyses\u2014including Reporting Odds Ratio (ROR) and Proportional Reporting Ratio (PRR)\u2014were conducted to identify significant cardiovascular safety signals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Different ADT agents exhibited distinct cardiovascular AE profiles. Some drugs were linked to a broader range of CVD\u2010related AEs, while others had more limited associations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>ADT agents demonstrate heterogeneous cardiotoxicity profiles. These findings emphasize the need for individualized treatment strategies, particularly in patients with pre\u2010existing CVD risks, and may aid clinicians in balancing cancer control with cardiovascular safety.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/cam4.71487","type":"journal-article","created":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T04:09:57Z","timestamp":1766376597000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Cardiovascular Safety Landscape of\n                    <scp>ADT<\/scp>\n                    in Prostate Cancer Treatment Based on Real\u2010World Analysis"],"prefix":"10.1002","volume":"14","author":[{"given":"Wei","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Urology Beijing Anzhen Hospital, Capital Medical University  Beijing P. R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zirui","family":"Dong","sequence":"additional","affiliation":[{"name":"Department of Urology Union Hospital, Tongji Medical College, Huazhong University of Science and Technology  Wuhan Hubei P. R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baoan","family":"Hong","sequence":"additional","affiliation":[{"name":"Department of Urology Beijing Anzhen Hospital, Capital Medical University  Beijing P. R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Guan","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine First Hospital of Shanxi Medical University, Shanxi Medical University  Taiyuan Shanxi P. R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxuan","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Urology Beijing Anzhen Hospital, Capital Medical University  Beijing P. R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhipeng","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Urology Beijing Anzhen Hospital, Capital Medical University  Beijing P. R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Miao","sequence":"additional","affiliation":[{"name":"Department of Urology Beijing Anzhen Hospital, Capital Medical University  Beijing P. R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-8108-6910","authenticated-orcid":false,"given":"Ning","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Urology Beijing Anzhen Hospital, Capital Medical University  Beijing P. R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,12,21]]},"reference":[{"key":"e_1_2_11_2_1","unstructured":"R. L.Siegel T. B.Kratzer A. N. G.Msph H.Sung andA. J.Dvm \u201cCancer Statistics \u201d(2025)."},{"issue":"6","key":"e_1_2_11_3_1","first-page":"835","article-title":"Cardiovascular Risk in Prostate Cancer: JACC: CardioOncology State\u2010of\u2010the\u2010Art Review","volume":"6","author":"Leong D. P.","year":"2024","journal-title":"Cardio\u2010Oncology"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2010-0338"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/8145173"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.06.011"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2024.03.027"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2024.04.010"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2011.1745"},{"key":"e_1_2_11_10_1","first-page":"613","article-title":"Cardiovascular Effects of GnRH Antagonists Compared With Agonists in Prostate Cancer","volume":"5","author":"Nelson A. J.","year":"2023","journal-title":"Cardio\u2010Oncology"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2020.06.002"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2024.10.005"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2024.08.031"},{"key":"e_1_2_11_14_1","unstructured":"U.S. Food & Drug Administration \u201cFDA Adverse Event Reporting System (FAERS) Public Dashboard \u201d(2021) https:\/\/www.fda.gov\/drugs\/questions\u2010and\u2010answers\u2010fdas\u2010adverse\u2010event\u2010reporting\u2010system\u2010faers\/fda\u2010adverse\u2010event\u2010reporting\u2010system\u2010faers\u2010public\u2010dashboard."},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2017.280"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2021.100887"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01688-3"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-023-01094-z"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab482"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)02391-6"},{"key":"e_1_2_11_21_1","first-page":"3","article-title":"Recognition, Prevention, and Management of Arrhythmias and Autonomic Disorders in Cardio\u2010Oncology: A Scientific Statement From the American Heart Association","volume":"144","author":"Fradley M. G.","year":"2021","journal-title":"Atrial Fibrillation"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2024.0860"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2024.1549"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2019.07.031"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.08.061"}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.71487","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T11:26:19Z","timestamp":1766748379000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.71487"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":24,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10.1002\/cam4.71487"],"URL":"https:\/\/doi.org\/10.1002\/cam4.71487","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"value":"2045-7634","type":"print"},{"value":"2045-7634","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"2025-06-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-12","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e71487"}}